⌘K
t
On August 21, 2025, BioPharma Credit PLC issued a correction to its August 20, 2025 announcement, stating it had purchased 100,000 of its ordinary shares into treasury through J.P. Morgan Securities plc. The corrected lowest and highest price per share for this transaction was $0.8860, amending the previously reported $0.8900. Following this purchase, the Company holds 244,704,289 ordinary shares in treasury, with 1,129,227,778 ordinary shares in issue and total voting rights.
| Date | 21 Aug 2025 |
| Time | 12:07:17 |
| Category | Capital structure |
| ID | 2994W |
BIOPHARMA CREDIT PLC
(THE "COMPANY")
TRANSACTION IN OWN SHARES - Correction
The following correction has been made to the Transaction in Own shares announcement released on 20 August 2025 at 18:16.
The highest and lowest price per share has been corrected from $0.8900 pence per Ordinary share to $0.8860 pence per Ordinary share. All other details remain unchanged.
The full amended announcement is shown below.
BioPharma Credit plc
(the "Company")
TRANSACTION IN OWN SHARES
BioPharma Credit PLC announces that today it has purchased the following number of its ordinary shares of US $0.01 each through J.P. Morgan Securities plc into treasury.
Ordinary Shares: BPCR LN
Date of purchase: 20 August 2025
Number of ordinary shares purchased: 100,000
Lowest price per share: $0.8860
Highest price per share: $0.8860
Trading venue: LSE
Aggregate volume per date per trading venue: 100,000
Weighted average price per day per trading venue: $0.8860
Following the above transaction, the Company holds 244,704,289 of its ordinary shares in treasury and has 1,129,227,778 ordinary shares in issue (excluding treasury shares). Therefore, the total number of voting rights in the Company is 1,129,227,778. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
Enquiries:
BioPharma Credit plc
via MUFG Corporate Governance Limited
Company Secretary
+44 (0) 333 300 1932
Burson Buchanan
Mark Court / Jamie Hooper / Henry Wilson / Samuel Adams
+44 (0)20 7466 5000
biopharmacredit@buchanan.uk.com
Notes to Editors:
BioPharma Credit PLC is London's only specialist debt investor to the life sciences industry and joined the LSE in March 2017. BioPharma Credit PLC seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. BioPharma Credit PLC seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.
LEI: 213800AV55PYXAS7SY24